Introducing the Gene & Cell Therapy Study Group of the ASNR, ASFNR, and ASPNR

References

1. 1.↵
   1. Gao J,
   2. Gunasekar S,
   3. Xia ZJ, et al

   . Gene therapy for CNS disorders: modalities, delivery and translational challenges. Nat Rev Neurosci 2024;25:553–72.doi:10.1038/s41583-024-00829-7 pmid:38898231

   CrossRefPubMed
2. 2.↵
   1. Eichler FS,
   2. Brown RH

   . Gene therapy for neurologic disorders. Neurotherapeutics 2024;21:e00453 doi:10.1016/j.neurot.2024.e00453 pmid:39318035

   CrossRefPubMed
3. 3.↵
   1. Chen KS,
   2. Koubek EJ,
   3. Sakowski SA, et al

   . Stem cell therapeutics and gene therapy for neurologic disorders. Neurotherapeutics 2024;21:e00427 doi:10.1016/j.neurot.2024.e00427 pmid:39096590

   CrossRefPubMed
4. 4.↵
   1. Eichler F,
   2. Duncan CN,
   3. Musolino PL, et al

   . Lentiviral gene therapy for cerebral adrenoleukodystrophy. N Engl J Med 2024;391:1302–12 doi:10.1056/NEJMoa2400442 pmid:39383459

   CrossRefPubMed
5. 5.↵
   1. Miller TM,
   2. Cudkowicz ME,
   3. Genge A, et al

   ; VALOR and OLE Working Group. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med 2022;387:1099–110 doi:10.1056/NEJMoa2204705 pmid:36129998

   CrossRefPubMed
6. 6.↵
   1. Fumagalli F,
   2. Calbi V,
   3. Natali Sora MG, et al

   . Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access. Lancet 2022;399:372–83 doi:10.1016/S0140-6736(21)02017-1 pmid:35065785

   CrossRefPubMed
7. 7.↵
   1. Mendell JR,
   2. Al-Zaidy S,
   3. Shell R, et al

   . Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 2017;377:1713–22 doi:10.1056/NEJMoa1706198 pmid:29091557

   CrossRefPubMed
8. 8.↵
   1. Mercuri E,
   2. Darras BT,
   3. Chiriboga CA, et al

   ; CHERISH Study Group. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 2018;378:625–35 doi:10.1056/NEJMoa1710504 pmid:29443664

   CrossRefPubMed
9. 9.↵
   1. Tai CH,
   2. Lee NC,
   3. Chien YH, et al

   . Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency. Mol Ther 2022;30:509–18 doi:10.1016/j.ymthe.2021.11.005 pmid:34763085

   CrossRefPubMed
10. 10.↵
    1. Pearson TS,
    2. Gupta N,
    3. San Sebastian W, et al

    . Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons. Nat Commun 2021;12:4251 doi:10.1038/s41467-021-24524-8 pmid:34253733

    CrossRefPubMed
11. 11.↵
    1. Frangoul H,
    2. Locatelli F,
    3. Sharma A, et al

    ; CLIMB SCD-121 Study Group. Exagamglogene autotemcel for severe sickle cell disease. N Engl J Med 2024;390:1649–62 doi:10.1056/NEJMoa2309676 pmid:38661449

    CrossRefPubMed
12. 12.↵
    Quarterly Gene, Cell, and RNA Therapy Landscape Report. ASGCT, American Society of Gene & Cell Therapy. https://www.asgct.org/publications/landscape-report. Accessed January 15, 2025
13. 13.↵
    1. Mattar CNZ,
    2. Chew WL,
    3. Lai PS

    . Embryo and fetal gene editing: technical challenges and progress toward clinical applications. Mol Ther Methods Clin Dev 2024;32:101229 doi:10.1016/j.omtm.2024.101229 pmid:38533521

    CrossRefPubMed
14. 14.↵
    1. Piguet F,
    2. de Saint Denis T,
    3. Audouard E, et al

    . The challenge of gene therapy for neurological diseases: strategies and tools to achieve efficient delivery to the central nervous system. Hum Gene Ther 2021;32:349–74 doi:10.1089/hum.2020.105 pmid:33167739

    CrossRefPubMed
15. 15.↵
    1. Daci R,
    2. Flotte TR

    . Delivery of adeno-associated virus vectors to the central nervous system for correction of single gene disorders. Int J Mol Sci 2024;25:1050 doi:10.3390/ijms25021050 pmid:38256124

    CrossRefPubMed
16. 16.↵
    1. Kofoed RH,
    2. Aubert I

    . Focused ultrasound gene delivery for the treatment of neurological disorders. Trends Mol Med 2024;30:263–77 doi:10.1016/j.molmed.2023.12.006 pmid:38216449

    CrossRefPubMed
17. 17.↵
    1. Shah BR,
    2. Tanabe J,
    3. Jordan JE, et al

    . State of practice on transcranial MR-guided focused ultrasound: a report from the ASNR Standards and Guidelines Committee and ACR Commission on Neuroradiology Workgroup. AJNR Am J Neuroradiol 2025;46:2–10 doi:10.3174/ajnr.A8405 pmid:39572202

    Abstract/FREE Full Text
18. 18.↵
    1. Daci R,
    2. Gray-Edwards H,
    3. Shazeeb MS, et al

    . Neuroimaging applications for the delivery and monitoring of gene therapy for central nervous system diseases. Hum Gene Ther 2024;35:886–95 doi:10.1089/hum.2024.057 pmid:39323316

    CrossRefPubMed
19. 19.↵
    1. Biswas A,
    2. Soo AKS,
    3. Kurian MA, et al

    ; IMaging Assessment in Gene and Enzyme Replacement therapies (IMAGER) study group. Imaging readiness in the gene therapy era-exploring standardized protocols for response assessment. J Inherit Metab Dis 2025;48:e12828 doi:10.1002/jimd.12828 pmid:39648747

    CrossRefPubMed